Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.

Who Are the Key Players in the Kymriah Market? The Kymriah market is dominated by Novartis AG, a key player in CAR-T cell therapy innovation. Advancements in Kymriah and other CAR-T therapies have ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen receptor T-cell therapy, according to results of a retrospective cohort ...

The rates among those who were treated with tisagenlecleucel (tisa-cel; Kymriah; Novartis) and did or did not experience ICANS were 82% and 29%, respectively, and for recent falls, 27% and 13%.

Following the commercial launch in 2017 of partner Novartis’s CAR-T Kymriah (in r/r paediatric ALL), Oxford BioMedica plc (LON:OXB) has become one of a handful of regulatory... Oxford BioMedica ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

Kymriah (tisagenlecleucel) is a prescription drug that’s used to treat certain types of leukemia and lymphoma. The drug is given as an intravenous (IV) infusion. Kymriah is usually given as a ...

This article was coproduced with Kody Kester. Since last October, Novartis' shares have lagged the S&P 500 index. The pharmaceutical company's pipeline remains robust, which could translate into ...